Global Hyperoxaluria Drug Market, By Type (Primary Hyperoxaluria, Secondary Hyperoxaluria), Gene Type (AGXT, GRHPR, Others), Treatment Type (Medication, Surgery), Drugs (Calcium Oxalate Urinary Inhibitors, Thiazide Diuretics, Others), Mode of Administration (Injectable, Oral, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), End User (Hospitals, Homecare, Specialty Clinics, Others) – Industry Trends and Forecast to 2031.
Hyperoxaluria Drug Market Analysis and Size
The increase in the number of people suffering from hyperoxaluria across the globe acts as one of the major factors driving the growth of hyperoxaluria drug market. The increase in special designation from the regulatory authority, and rise in demand for drugs such as calcium oxalate urinary inhibitors, thiazide diuretics and others, for treating various complications of the disease accelerate the market growth. The development of technology offering therapies for specific treatment of the disorder, and growing number of acquisition strategies and company collaborations for research projects further influence the market. In addition, increase in demand of disease specific novel treatment, rise in support by public and private organizations and growth in awareness positively affect the hyperoxaluria drug market.
Data Bridge Market Research analyzes that the global hyperoxaluria drug market was valued at USD 18.23 million in 2023 and is expected to reach USD 43.00 million by 2031, registering a CAGR of 6.6% during the forecast period. ‘Biotechnology companies” accounts for the largest end user segment in the respective market due to the high demand for minimally aesthetic procedures among people. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Hyperoxaluria Drug Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2024 to 2031
|
|
Base Year
|
2023
|
|
Historic Years
|
2022 (Customizable to 2016-2021)
|
|
Quantitative Units
|
Revenue in USD Million, Pricing in USD
|
|
Segments Covered
|
By Type (Primary Hyperoxaluria, Secondary Hyperoxaluria), Gene Type (AGXT, GRHPR, Others), Treatment Type (Medication, Surgery), Drugs (Calcium Oxalate Urinary Inhibitors, Thiazide Diuretics, Others), Mode of Administration (Injectable, Oral, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), End User (Hospitals, Homecare, Specialty Clinics, Others)
|
|
Countries Covered
|
U.S., Canada, Mexico, Peru, Brazil, Argentina, Rest of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia Pacific, South Africa, Saudi Arabia, U.A.E., Kuwait, Israel, Egypt, Rest of Middle East and Africa
|
|
Market Players Covered
|
Allena Pharmaceuticals, Inc. (U.S.), Intellia Therapeutics, Inc. (U.S.), OxThera (Sweden), Dicerna Pharmaceuticals, Inc. (U.S.), Alnylam Pharmaceuticals, Inc. (U.S.), Pfizer Inc. (U.S.), and Sanofi (France)
|
|
Market Opportunities
|
|
Market Definition
Hyperoxaluria refers to an ultra-rare metabolic disorder that is generally characterized by excessive oxalate production resulting in the deposition of calcium oxalate crystals in the kidneys and urinary tract. The disorder may lead to the formation of painful and recurrent kidney stones and nephrocalcinosis.
Global Hyperoxaluria Drug Market Dynamics
Drivers
- Increased Awareness and Diagnosis
Growing awareness about hyperoxaluria and improved diagnostic capabilities may lead to an increase in the number of diagnosed cases, driving the demand for effective drugs. As awareness grows, more individuals with symptoms of hyperoxaluria may seek medical attention and receive a proper diagnosis. This can lead to an expanded patient pool for hyperoxaluria drugs and treatments, thereby driving market growth.
- Research and Development
Advances in research and development efforts to discover novel drugs and therapies for hyperoxaluria can drive market growth. Collaborations between pharmaceutical companies, research institutions, and government bodies may play a crucial role in this. With greater R&D investment, pharmaceutical companies can explore new avenues for treating hyperoxaluria. This may involve identifying novel drug targets, developing innovative therapies, or repurposing existing medications for hyperoxaluria treatment.
Opportunities
- Focus on Rare Diseases
The pharmaceutical industry has been showing an increasing interest in rare diseases, and hyperoxaluria, being a relatively rare condition, could attract attention from pharmaceutical companies. Increased attention to rare diseases often leads to greater awareness among healthcare professionals and the general public. This can result in more individuals with hyperoxaluria being properly diagnosed, leading to an expanded patient population for hyperoxaluria drugs.
- Orphan Drug Designation
Given the often rare nature of hyperoxaluria, drugs targeting this condition may qualify for orphan drug designation, providing certain regulatory and financial incentives to developers. Orphan drug designation typically grants exclusive marketing rights to the sponsor company for a specified period (e.g., seven years in the United States). This exclusivity provides a competitive advantage by limiting competition from other drug manufacturers, allowing the company to recoup its investment in research and development.
Restraints/Challenges
- Stringent Regulatory Requirements
Stringent regulatory requirements for drug approval can pose a challenge, delaying the introduction of new hyperoxaluria drugs to the market. Stringent regulatory requirements help ensure that hyperoxaluria drugs undergo thorough testing to demonstrate their safety and efficacy before being approved for market use. This protects patients from potential harm and ensures that they receive treatments that are effective in managing their condition.
- High Development Costs
The high costs associated with the research and development of pharmaceuticals, coupled with the uncertainty of success in clinical trials, can be a significant restraint. Developing a new drug, from initial discovery to regulatory approval, involves significant expenses. Researching hyperoxaluria, understanding its underlying mechanisms, and identifying potential drug candidates require substantial investment in laboratory research, preclinical studies, and clinical trials.
This hyperoxaluria drug market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the hyperoxaluria drug market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Hyperoxaluria Drug Market Scope
The hyperoxaluria drug market is segmented on the basis of type, gene type, treatment type, drugs, mode of administration, distribution channel and end user. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
Type
- Primary Hyperoxaluria
- Secondary Hyperoxaluria
Gene Type
- AGXT
- GRHPR
- Others
Treatment Type
- Medication
- Surgery
Drugs
- Calcium Oxalate Urinary Inhibitors
- Thiazide Diuretics
- Others
Mode of Administration
- Injectable
- Oral
- Others
Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
End User
- Hospitals
- Homecare
- Specialty Clinics
Global Hyperoxaluria Drug Market Regional Analysis/Insights
The hyperoxaluria drug market is analyzed and market size information is provided by country, type, gene type, treatment type, drugs, mode of administration, distribution channel and end user as referenced above.
The countries covered in the market report are the U.S., Canada, Mexico, Germany, U.K., France, Italy, Spain, Russia, Poland, Switzerland, Netherlands, Hungary, Austria, Norway, Ireland, Turkey, Lithuania, rest of Europe, China, Japan, India, Australia, South Korea, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, rest of Asia-Pacific, Brazil, Argentina, Peru, rest of South America, South Africa, Saudi Arabia, U.A.E., Israel, Kuwait, Egypt, and rest of Middle East & Africa.
North America is expected to dominate the market due to the well-established healthcare infrastructure in the region. Asia-Pacific is expected to witness high growth due to the large patient population within the region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Patient Epidemiology Analysis
The hyperoxaluria drug market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analyzed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
The hyperoxaluria drug market also provides you with detailed market analysis for every country's growth in a particular industry with the hyperoxaluria drug market sales, impact of advancement in the hyperoxaluria drug market, and changes in regulatory scenarios with their support for the hyperoxaluria drug market. The data is available for the historical period 2012 to 2021.
Competitive Landscape and Global Hyperoxaluria Drug Market Share Analysis
The hyperoxaluria drug market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related hyperoxaluria drug market.
Some of the major players operating in the hyperoxaluria drug market are:
- Allena Pharmaceuticals, Inc.,(U.S.)
- Intellia Therapeutics, Inc., (U.S.)
- OxThera, (Sweden)
- Dicerna Pharmaceuticals, Inc., (U.S.)
- Alnylam Pharmaceuticals, Inc., (U.S.)
- Pfizer Inc., (U.S.)
- Sanofi, (France)
SKU-